Steven J. O’Day

Learn More
Intelligent Autonomy (IA) is a multi-year program within the Office of Naval Research (ONR) Autonomous Operations (AO) Future Naval Capabilities (FNC) program. The primary goal of the effort is to develop and demonstrate technologies for highly automated and fully autonomous mission planning and dynamic re-tasking of multiple classes of Naval unmanned(More)
The role of estrogen receptor A (ERA) in melanoma is unknown. ERA expression may be regulated in melanoma via hypermethylation of promoter CpG islands. We assessed ERA hypermethylation in primary and metastatic melanomas and sera as a potential tumor progression marker. ERA methyl-ation status in tumor (n = 107) and sera (n = 109) from American Joint(More)
Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable responses in advanced melanoma. However, less than 25% of those treated benefit, treatment is expensive, and side(More)
BACKGROUND Ipilimumab (IPI), an anti-CTLA-4 antibody, and vemurafenib (VEM), a BRAF inhibitor, have distinct mechanisms of action and shared toxicities (e.g., skin, gastrointestinal [GI] and hepatobiliary disorders) that may preclude concomitant administration. Concurrent administration of IPI and VEM previously showed significant dose-limiting(More)
BACKGROUND In patients with metastatic melanoma and KIT amplifications and/or mutations, therapy with imatinib mesylate may prolong survival. 18F-labeled 2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT may be used to assess metabolic response. We investigated associations of metabolic response, mutational status, progression-free survival and overall survival(More)
  • 1